MELBOURNE, Australia, 16 July 2023 – MGI Tech Co. Ltd. (MGI), a company committed to building core tools and technology to lead life science, today launched its global brand campaign, “What If?”, at the XXIII International Congress of Genetics (ICG), a five-yearly conference uniting the international genetics community. The campaign highlights MGI’s capabilities and solutions, introducing the brand to the global market, including Australia and New Zealand, and positioning MGI as a partner giving the scientific community another choice.
“The genomics industry in Australia and New Zealand faces challenges in accessibility, affordability, and speed,” said Dr. Bicheng Yang, Director of MGI Australia. “These obstacles hinder progress in both clinical and broader life science research. With the ‘What If?’ campaign, we reaffirm our commitment to overcoming these limitations by providing tools that deliver fast, cost-effective, and reliable results. Our goal is to empower scientists and healthcare professionals to unlock the full potential of genomics.”
Under “What If?”, MGI shifts the industry dialogue from platform comparisons to customer-focused solutions, encouraging researchers, scientists, and decision-makers to explore the possibilities of meeting their most pressing genomics needs.
What if cost was not a barrier?
MGI is ushering in a sub-$100 human genome era with the fully automated DNBSEQ-T20×2 sequencer, designed to meet even the most challenging sequencing demands. By integrating all components through robotics to process six slides per run, and consecutive robotic dipping of multiple slides in the same reagent, a single T20×2 can deliver up to 50,000 whole-genome sequences per year at under $100 per 30x human genome, including instrument depreciation.
What if speed, low cost, and flexibility were not a trade-off?
Powered by DNBSEQ™ technology, the DNBSEQ-T7 delivers high speed, flexibility, and ultra-high throughput. It can generate up to 7 Tb of high-quality data in just 24 hours. Its quadruple flow cell design allows one to four flow cells to run simultaneously but independently, accommodating different read lengths and applications in a single run. To date, T7 has supported multiple National Genome Projects in the UAE, Thailand, Indonesia, Brazil, and more.
What if targeted sequencing was only 24 hours away?
The DNBSEQ-G99 combines the speed of targeted testing with the flexibility of high-throughput sequencing. Its triangular matrix signal spots on the flow cell enable a higher data density, with throughput of 8–48 Gb per run. Ideal for targeted gene and small genome sequencing, G99 played a key role in identifying the first imported case of Monkeypox in Chongqing, China.
What if sequencing was more than just the sequencer?
MGI’s lab automation systems—including MGISTP-7000, MGISP-Smart 8, MGISP-NE384, MGISP-960, and others—enable high-throughput automated sample processing, nucleic acid extraction, and large-scale testing. Modular designs and customizable features allow laboratories to scale and adapt systems to their specific needs. The MGIGLab-L ultra-high throughput library preparation system can handle over 1,000 samples per day with minimal staff, offering convenience, accuracy, and efficiency.
What if genomics empowered communities?
MGI has advanced genomics to support local communities. During the COVID-19 Delta variant outbreak, MGI supplied Australia and New Zealand with proprietary testing equipment and kits nationwide. To date, MGI has supported over 80 countries in global pandemic responses.
What if data management was safer and more reliable?
The ZTRON Appliance, MGI’s GDPR-compliant automated genomics data platform, provides high-performance edge computing and storage for laboratory management, bioinformatics, data governance, and delivery. Scalable and deployable in laboratories or traditional data centers, ZTRON ensures safe and reliable genomics data management.
Backed by a comprehensive portfolio of ultra-high, high, and medium-throughput sequencers, MGI stands out with solutions tailored to diverse sequencing needs at competitive costs. Beyond sequencers, MGI offers an end-to-end solution including lab automation, single-cell platforms, and bioinformatics tools such as lab information management systems and data management centres. Through the “What If?” campaign, which will gradually roll out globally, MGI continues its commitment to empowering researchers to make breakthrough discoveries and improve human health.
What if I had a choice? What if? MGI!
For more information, WHAT IF?
